Quest Diagnostics Increases Dividend 7.6% To $0.71 Per Quarter; Announces $1 Billion Increase in Share Repurchase Authorization
Get Alerts DGX Hot Sheet
Overall Analyst Rating:
NEUTRAL ( Up)
Dividend Yield: 2.3%
EPS Growth %: -9.3%
Join SI Premium – FREE
SECAUCUS, N.J., Feb. 2, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today the Company's Board of Directors has authorized a 7.6% increase in its quarterly dividend from $0.66 to $0.71 per share. The increase is effective with the dividend payable on April 24, 2023 to shareholders of record of Quest Diagnostics common stock on April 10, 2023. With the increase, the annual dividend will be $2.84 per share. The company has raised its dividend annually since 2011.
Additionally, the Board of Directors has increased the Company's share repurchase authorization by $1 billion. The increased authority is in addition to the $311 million that was available as of December 31, 2022 under the Company's share repurchase program.
About Quest Diagnostics
Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our nearly 50,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. www.QuestDiagnostics.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/quest-diagnostics-increases-dividend-7-6-to-0-71-per-quarter-announces-1-billion-increase-in-share-repurchase-authorization-301736635.html
SOURCE Quest Diagnostics
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sharing Experiences for Mutual Success: Heilongjiang Ice and Snow Tourism link with Northern Europe as a silver silk ribbon
- FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
- Flash News: OKX Earn Gives Users Who Stake SUI the Opportunity to Claim a Share of 10,000 SUI Tokens
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Dividend, Stock BuybackSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!